Bristol-Myers Squibb Co. (BMY) Social Stream



Bristol-Myers Squibb Co. (BMY): $48.26

0.25 (-0.52%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

B

BRISTOL MYERS SQUIBB CO (BMY) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering BRISTOL MYERS SQUIBB CO.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-09 13 $80 $66 $73.222 $51.31 42.71%
2021-11-17 13 $80 $66 $72.875 $51.31 42.03%
2021-11-18 12 $80 $66 $72.875 $51.31 42.03%
2021-11-19 12 $80 $66 $72.777 $51.31 41.84%
2022-02-07 13 $80 $58 $71.3 $51.31 38.96%
2022-03-25 13 $80 $58 $71.5 $51.31 39.35%
2022-03-30 13 $81 $58 $72.4 $51.31 41.1%
2022-04-18 13 $81 $58 $72.2 $51.31 40.71%
2022-04-22 13 $85 $58 $73.7 $51.31 43.64%
2022-05-02 13 $85 $58 $74.272 $51.31 44.75%
2022-05-16 13 $92 $58 $75.818 $51.31 47.76%
2022-05-25 13 $92 $63 $76.909 $51.31 49.89%
2022-06-01 14 $92 $63 $78 $51.31 52.02%
2022-06-06 14 $92 $63 $78.181 $51.31 52.37%
2022-07-27 15 $92 $63 $78.181 $51.31 52.37%
2022-07-28 17 $92 $61 $79.083 $51.31 54.13%
2022-08-30 17 $92 $61 $78.769 $51.31 53.52%
2022-09-20 17 $94 $61 $79.615 $51.31 55.16%
2022-10-12 18 $94 $61 $79.615 $51.31 55.16%
2022-10-26 18 $94 $61 $79.461 $51.31 54.86%
2022-10-31 17 $94 $60 $79.23 $51.31 54.41%
2022-12-06 17 $94 $60 $79.461 $51.31 54.86%
2023-01-09 17 $94 $60 $80.076 $51.31 56.06%
2023-01-26 18 $95 $60 $81.142 $51.31 58.14%
2023-02-03 18 $95 $60 $81.285 $51.31 58.42%
2023-02-15 18 $95 $62 $81.571 $51.31 58.98%
2023-04-10 19 $95 $62 $80.266 $51.31 56.43%
2023-04-17 19 $94 $62 $79.8 $51.31 55.53%
2023-04-21 19 $94 $62 $79.466 $51.31 54.87%
2023-04-27 19 $94 $62 $79.666 $51.31 55.26%
2023-04-28 19 $94 $59 $79.466 $51.31 54.87%
2023-05-22 19 $94 $59 $79.357 $51.31 54.66%
2023-06-20 18 $94 $59 $78.538 $51.31 53.07%
2023-07-11 18 $94 $59 $77.642 $51.31 51.32%
2023-07-18 18 $94 $56 $76.133 $51.31 48.38%
2023-07-19 18 $94 $56 $75.933 $51.31 47.99%
2023-07-25 18 $90 $56 $75.133 $51.31 46.43%
2023-07-28 18 $90 $56 $74.214 $51.31 44.64%
2023-09-14 18 $85 $56 $71.642 $51.31 39.63%
2023-10-04 18 $85 $56 $70.714 $51.31 37.82%
2023-10-11 18 $85 $56 $70.571 $51.31 37.54%
2023-10-16 17 $85 $56 $70.5 $51.31 37.4%
2023-10-25 17 $85 $56 $70.142 $51.31 36.7%
2023-10-27 18 $85 $50 $65.533 $51.31 27.72%
2023-10-31 18 $85 $50 $63.625 $51.31 24%
2023-11-02 18 $85 $50 $63.058 $51.31 22.9%
2023-11-16 19 $85 $50 $62.294 $51.31 21.41%
2023-11-20 20 $85 $50 $62.117 $51.31 21.06%
2023-12-22 20 $85 $42 $61.647 $51.31 20.15%
2023-12-26 21 $85 $42 $61.647 $51.31 20.15%
2023-12-27 21 $85 $42 $61.222 $51.31 19.32%
2023-12-29 21 $85 $42 $61 $51.31 18.89%

The Trend in the Analyst Price Target


BMY's average price target has moved down $17.18 over the prior 19 months.

Over the past 51 weeks, BMY's average upside potential has been 19.26%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-01-03 17 94 60 80.076 72.26 10.82%
2023-07-19 18 94 56 75.933 62.06 22.35%
2023-10-02 18 85 56 70.714 57.85 22.24%
2023-11-16 19 85 50 62.294 50.84 22.53%
2023-12-14 20 85 42 61.647 51.47 19.77%

BMY Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.49 6 0 14 1 1 21

The Trend in the Broker Recommendations


BMY's average broker recommendation rating worsened by 0.3 over the prior 43 weeks.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for BMY as an investment opportunity.

  • In the context of all US stocks, BRISTOL MYERS SQUIBB CO's number of analysts covering the stock is greater than 5461.3% of them.
  • In terms of how BRISTOL MYERS SQUIBB CO fares relative to Pharmaceutical Products stocks, note that its average analyst price target is greater than 5190.92% of that group.
  • BRISTOL MYERS SQUIBB CO's upside potential (average analyst target price relative to current price) is higher than 5046.32% of stocks in the large market cap category.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, BRISTOL MYERS SQUIBB CO's variance in analysts' estimates is lower than -1690.57% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to BRISTOL MYERS SQUIBB CO are DNLI, ARGX, and CRSP.

Make investment decisions regarding BMY using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!